Discovering a Novel Mechanism Underlying LRRK2 Kinase Activity in Genetic & Sporadic Parkinson’s Disease Populations
Time: 12:00 pm
day: Conference Day One - Track One
Details:
- Leveraging patient-derived cell and animal model systems to investigate how 15-Lipoxygenase regulates LRRK2 kinase hyperactivity in PD
- Highlighting the potential of 15-Lipoxygenase inhibitors as a novel therapeutic approach to safely modify LRRK2 kinase activity and treat PD
